2729-36-4

Basic information

• Product Name: 3,4-Dichloro-6-fluoroaniline
• Synonyms: 3,4-Dichloro-6-fluoroaniline;4,5-Dichloro-2-fluoroaniline
• CAS NO: 2729-36-4
• Molecular Formula: C₆H₄Cl₂FN
• Molecular Weight: 180.0070632
• Mol File: 2729-36-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 251.8°Cat760mmHg
• Flash Point: 106.1°C
• Appearance: /
• Density: 1.502g/cm³
• Vapor Pressure: 0.02mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.51±0.10(Predicted)
• CAS DataBase Reference: 3,4-Dichloro-6-fluoroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dichloro-6-fluoroaniline(2729-36-4)
• EPA Substance Registry System: 3,4-Dichloro-6-fluoroaniline(2729-36-4)

Safety Data

• HazardClass: 6.1
• Hazardous Substances Data: 2729-36-4(Hazardous Substances Data)

Usage

Uses

3,4-Dichloro-6-fluoroaniline is used as pharmaceutical intermediates

InChI:InChI=1/C6H4Cl2FN/c7-3-1-5(9)6(10)2-4(3)8/h1-2H,10H2

Upstream product

• 35754-37-1 1,2-dichloro-3-fluoro-5-nitrobenzene 
• 6306-39-4 1,2-dichloro-4,5-dinitrobenzene 
• 2339-78-8 1,2-dichloro-4-fluoro-5-nitrobenzene 
• 7440-02-0 nickel 
• 1435-49-0 3,4-dichlorofluorobenzene 

Downstream Products

• 128924-45-8 C₁₄H₁₁Cl₂FN₂O₃S 
• 848006-02-0 4-[(3,4-dichloro-6-fluorophenyl)amino]-7-fluoro-6-nitroquinazoline 
• 952741-29-6 2-bromo-N-(4,5-dichloro-2-fluoro-phenyl)-acetamide 
• 455922-81-3 6-amino-4-(4,5-dichloro-2-fluorophenylamino)quinazoline 
• 91214-86-7 4,5-dichloro-N-(3-dimethylaminopropyl)-benzene-1,2-diamine 
• 1000572-78-0 1-Bromo-4,5-dichloro-2-fluorobenzene 
• 874773-69-0 4,5-dichloro-2-fluorobenzenesulphonamide 
• 733009-42-2 TKS 050 
• 1400741-90-3 N-[4-[(4,5-dichloro-2-fluorophenyl)amino]quinazolin-6-yl]-2-hydrazinylacetamide 
• 1400741-91-4 N-[4-[(4,5-dichloro-2-fluorophenyl)amino]quinazolin-6-yl]-2-(5-sulfanyl-2-sulfanylidene-2,3-dihydro-1,3,4-thiadiazol-3-yl)acetamide 
• 1400741-92-5 N-[4-[(4,5-dichloro-2-fluorophenyl)amino]quinazolin-6-yl]-2-[5-[(2,5-dioxooxolan-3-yl)sulfanyl]-2-sulfanylidene-2,3-dihydro-1,3,4-thiadiazol-3-yl]acetamide 
• 1400741-85-6 2-([4-[([4-[(4,5-dichloro-2-fluorophenyl)amino]quinazolin-6-yl]carbamoyl)methyl]-5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl]sulfanyl)butanedioic acid 

Relevant articles and documents

Cobalt in N-doped carbon matrix catalyst for chemoselective hydrogenation of nitroarenes

Anilines as important intermediates for both organic synthesis and industrial manufactory are densely substituted with a variety of functional moieties, and the transformation of nitroarenes into corresponding anilines requires catalytically selective hydrogenation catalyst. Herein, we describe a simple pyrolysis strategy to prepare cobalt catalysts in nitrogen-doped carbon matrix applied in the selective hydrogenation of nitroarenes with molecular hydrogen. The Co/NC catalysts are obtained through thermal treatment of mixed precursors of cobalt phthalocyanine and melamine. The surface-modified Co particles with Co3O4 and CoNx sites are surrounded by N-doped carbon layers according to a series of structural characterization results. These Co/NC catalysts are capable of efficiently selective hydrogenation of nitrobenzene and various substituted nitroarenes into corresponding anilines under relatively mild reaction conditions. The optimal catalytic hydrogenation performance is contributed to the fast rate of H2 dissociated activation on the CoNx active sites and the facile adsorption of the reactant substances, which is verified by the isotopic H2-D2 exchange experiments, reactant adsorption and the ORR reaction tests. Furthermore, the heterogeneous Co/NC catalyst is highly stable without the Co leaching and deactivation issues during the recycling reaction runs.

METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES

This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for inhibiting cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EG

Epidermal growth factor receptor binding compounds for positron emission tomography

A radiolabeled compound of a formula: is described. R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, carboxy, carbalkoxy and salts thereof; and A, B, C and D are each independently s